TABLE 1.
OVERALL SUBJECT CHARACTERISTICS*
| Healthy Control Subjects | Subjects with Asthma | P Value | |
|---|---|---|---|
| Sample size | 28 | 42 | — |
| Age, years | 36 ± 9 | 36 ± 11 | 0.98 |
| Gender, M:F (% F) | 12:16 (56) | 17:25 (60) | 0.84 |
| Ethnicity | |||
| White | 20 | 18 | 0.012 |
| African American | 0 | 8 | |
| Hispanic | 3 | 11 | |
| Asian/Pacific Islander | 5 | 5 | |
| FEV1, % predicted | 107 ± 13% | 87 ± 12% | <0.0001 |
| ΔFEV1 with albuterol (% of baseline) | 2.7 ± 3.4% | 11.1 ± 8.7% | <0.0001 |
| Methacholine PC20 | 64 (22–64) | 0.43 (0.05–7.3) | <0.0001 |
| IgE, IU/ml | 27 (3–287) (n = 26) | 214 (19–2627) | <0.0001 |
| Blood eosinophils, ×109/L | 0.10 ± 0.07 | 0.31 ± 0.22 | <0.0001 |
Definition of abbreviation: PC20 = provocative concentration required to cause a 20% decline in FEV1.
*
Values are presented as mean ± SD or median (range) unless otherwise specified. For significance testing of PC20 and IgE, data were log transformed for normality. In case of missing data, number of subjects for whom data exist are noted.